The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in ...
Opinion
19hon MSNOpinion
Trump’s ‘God Squad’ pits energy vs. endangered species, but it’s a false choice – protecting wildlife can be good for business
There’s a well-worn debate in U.S. politics that goes something like this: Would you rather have abundant and affordable energy or a clean, healthy planet where wildlife can flourish? It sounds like ...
Cardiologists from NYU Langone Heart will present their latest clinical findings and research at the American College of Cardiology's Annual Scientific Session, ACC.26, held March 28 to 30 in New ...
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results